EUVIMEDEUVIMED entdecken
Crossref

Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation

Jaghatha Therassama, Justus Oliver Jaslin Edward, Somasundaram Arumugam, Pavazhaviji Pazhani, Jose Prakash Dharmian

Journal of Pharmaceutical Innovation · 2026-08 · 21 (4)

DOI: 10.1007/s12247-026-10573-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Innovation, online erschienen am 12.04.2026. Verfasst von Jaghatha Therassama und 4 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Therassama, J., Edward, J. O. J., Arumugam, S., Pazhani, P., & Dharmian, J. P. (2026). Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation. Journal of Pharmaceutical Innovation, 21(4). https://doi.org/10.1007/s12247-026-10573-3

Vancouver

Therassama J, Edward JOJ, Arumugam S, Pazhani P, Dharmian JP. Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation. Journal of Pharmaceutical Innovation. 2026;21(4). doi:10.1007/s12247-026-10573-3

BibTeX
@article{Therassama2026,
  author = {Therassama, Jaghatha and Edward, Justus Oliver Jaslin and Arumugam, Somasundaram and Pazhani, Pavazhaviji and Dharmian, Jose Prakash},
  title = {Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation},
  journal = {Journal of Pharmaceutical Innovation},
  year = {2026},
  volume = {21},
  number = {4},
  doi = {10.1007/s12247-026-10573-3}
}
Kostenlos starten →